At the molecular levels, sorafenib treatment reduces the expression of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), effectively inhibiting cancer metastasis and promoting tumor death [53]. This evidence concerns the gene KDR and cancer.